The use of a paired study design allowed us to develop a prediction strategy that was independent of all markers currently used in the clinic, identifying ultralow and low‐risk patients with ER negative, ERBB2 positive tumors and tumor diameters larger than 2 cm. Here, ERBB2 is linked to neoplasm.